Piwi	B-GP
Genes	O
Are	O
Dispensable	O
for	O
Normal	O
Hematopoiesis	O
in	O
Mice	B-OG

Competing	O
Interests	O
:	O
The	O
authors	O
declare	O
no	O
competing	O
interests	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
MN	O
EC	O
HL	O
.	O

Performed	O
the	O
experiments	O
:	O
MN	O
EC	O
SG	O
.	O

Analyzed	O
the	O
data	O
:	O
MN	O
EC	O
SG	O
HL	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
EC	O
SG	O
.	O

Wrote	O
the	O
paper	O
:	O
MN	O
HL	O
EC	O
.	O

Hematopoietic	O
stem	O
cells	O
(	O
HSC	O
)	O
must	O
engage	O
in	O
a	O
life	O
-	O
long	O
balance	O
between	O
self	O
-	O
renewal	O
and	O
differentiation	O
to	O
sustain	O
hematopoiesis	O
.	O

The	O
highly	O
conserved	O
PIWI	B-GP
protein	O
family	O
regulates	O
proliferative	O
states	O
of	O
stem	O
cells	O
and	O
their	O
progeny	O
in	O
diverse	O
organisms	O
.	O

A	O
Human	B-OG
piwi	B-GP
gene	O
(	O
for	O
clarity	O
,	O
the	O
non	O
-	O
italicized	O
“	O
piwi	B-GP
”	O
refers	O
to	O
the	O
gene	O
subfamily	O
),	O
HIWI	B-GP
(	O
PIWIL1	B-GP
),	O
is	O
expressed	O
in	O
CD34	B-GP
+	O
stem	O
/	O
progenitor	O
cells	O
and	O
transient	O
expression	O
of	O
HIWI	B-GP
in	O
a	O
human	B-OG
leukemia	B-DS
cell	O
line	O
drastically	O
reduces	O
cell	O
proliferation	O
,	O
implying	O
the	O
potential	O
function	O
of	O
these	O
proteins	O
in	O
hematopoiesis	O
.	O

Here	O
,	O
we	O
report	O
that	O
one	O
of	O
the	O
three	O
piwi	B-GP
genes	O
in	O
mice	B-OG
,	O
Miwi2	B-GP
(	O
Piwil4	B-GP
),	O
is	O
expressed	O
in	O
primitive	O
hematopoetic	O
cell	O
types	O
within	O
the	O
bone	O
marrow	O
.	O

Mice	B-OG
with	O
a	O
global	O
deletion	O
of	O
all	O
three	O
piwi	B-GP
genes	O
,	O
Miwi	B-GP
,	O
Mili	B-GP
,	O
and	O
Miwi2	B-GP
,	O
are	O
able	O
to	O
maintain	O
long	O
-	O
term	O
hematopoiesis	O
with	O
no	O
observable	O
effect	O
on	O
the	O
homeostatic	O
HSC	O
compartment	O
in	O
adult	O
mice	B-OG
.	O

The	O
PIWI	B-GP
-	O
deficient	O
hematopoetic	O
cells	O
are	O
capable	O
of	O
normal	O
lineage	O
reconstitution	O
after	O
competitive	O
transplantation	O
.	O

We	O
further	O
show	O
that	O
the	O
three	O
piwi	B-GP
genes	O
are	O
dispensable	O
during	O
hematopoietic	O
recovery	O
after	O
myeloablative	O
stress	O
by	O
5	O
-	O
FU	O
.	O

Collectively	O
,	O
our	O
data	O
suggest	O
that	O
the	O
function	O
of	O
the	O
piwi	B-GP
gene	O
subfamily	O
is	O
not	O
required	O
for	O
normal	O
adult	O
hematopoiesis	O
.	O

Introduction	O

Hematopoiesis	O
is	O
driven	O
by	O
a	O
rare	O
population	O
of	O
cells	O
called	O
hematopoietic	O
stem	O
cells	O
(	O
HSCs	O
).	O

These	O
cells	O
harbor	O
the	O
ability	O
to	O
repopulate	O
all	O
cell	O
lineages	O
within	O
the	O
blood	O
system	O
,	O
throughout	O
the	O
lifetime	O
of	O
an	O
animal	B-OG
.	O

Human	B-OG
hematopoietic	O
stem	O
and	O
progenitor	O
cells	O
are	O
characterized	O
by	O
their	O
expression	O
of	O
CD34	B-GP
[	O
1	O
]–[	O
4	O
].	O

Therefore	O
,	O
CD34	B-GP
expression	O
can	O
serve	O
as	O
an	O
indicator	O
of	O
self	O
-	O
renewal	O
capacity	O
.	O

Previously	O
,	O
it	O
was	O
shown	O
that	O
one	O
of	O
the	O
four	O
human	B-OG
homologs	O
of	O
Drosophila	B-OG
piwi	B-GP
,	O
PIWIL1	B-GP
(	O
a	O
.	O
k	O
.	O
a	O
.,	O
HIWI	B-GP
),	O
is	O
expressed	O
in	O
CD34	B-GP
+	O
cells	O
of	O
normal	O
human	B-OG
peripheral	O
blood	O
[	O
5	O
].	O

This	O
expression	O
is	O
quickly	O
lost	O
when	O
these	O
cells	O
are	O
differentiated	O
to	O
the	O
myeloid	O
lineage	O
in	O
culture	O
[	O
5	O
],	O
suggesting	O
that	O
piwi	B-GP
expression	O
is	O
correlated	O
with	O
undifferentiated	O
cell	O
states	O
within	O
the	O
human	B-OG
blood	O
system	O
.	O

In	O
addition	O
,	O
when	O
HIWI	B-GP
was	O
transiently	O
expressed	O
in	O
the	O
leukemic	O
cell	O
line	O
KG1	O
,	O
these	O
cells	O
were	O
drastically	O
reduced	O
in	O
their	O
proliferation	O
ability	O
[	O
5	O
].	O

Yet	O
,	O
in	O
mice	B-OG
,	O
piwi	B-GP
gene	O
expression	O
was	O
found	O
to	O
correlate	O
with	O
increased	O
proliferative	O
capacity	O
in	O
cells	O
of	O
the	O
blood	O
system	O
,	O
as	O
ectopic	O
expression	O
of	O
the	O
PIWIL2	B-GP
homolog	O
(	O
a	O
.	O
k	O
.	O
a	O
.,	O
Mili	B-GP
),	O
one	O
of	O
the	O
three	O
piwi	B-GP
genes	O
in	O
mice	B-OG
,	O
promoted	O
expansion	O
of	O
hematopoetic	O
cells	O
in	O
culture	O
[	O
6	O
].	O

These	O
interesting	O
,	O
but	O
somewhat	O
conflicting	O
observations	O
,	O
point	O
to	O
the	O
pressing	O
need	O
for	O
a	O
loss	O
-	O
of	O
-	O
function	O
study	O
to	O
clearly	O
define	O
the	O
role	O
,	O
if	O
any	O
,	O
of	O
PIWI	B-GP
proteins	O
in	O
hematopoiesis	O
.	O

PIWI	B-GP
proteins	O
are	O
known	O
to	O
bind	O
small	O
non	O
-	O
coding	O
RNAs	O
,	O
called	O
PIWI	B-GP
-	O
interacting	O
RNAs	O
(	O
piRNAs	O
)	O
[	O
7	O
]–[	O
16	O
]	O
and	O
have	O
highly	O
conserved	O
roles	O
in	O
germline	O
development	O
,	O
gametogenesis	O
,	O
transposon	O
silencing	O
,	O
and	O
epigenetic	O
regulation	O
.	O

Our	O
studies	O
of	O
the	O
piwi	B-GP
genes	O
in	O
Drosophila	B-OG
,	O
C	B-OG
.	I-OG
elegans	I-OG
,	O
mice	B-OG
,	O
and	O
humans	B-OG
,	O
together	O
with	O
studies	O
of	O
piwi	B-GP
-	I-GP
like	I-GP
genes	I-GP
in	O
Arabidopsis	B-OG
,	O
by	O
others	O
,	O
indicate	O
that	O
PIWI	B-GP
subfamily	O
proteins	O
represent	O
the	O
only	O
known	O
class	O
of	O
proteins	O
with	O
a	O
highly	O
conserved	O
function	O
for	O
stem	O
cell	O
self	O
-	O
renewal	O
in	O
both	O
animal	B-OG
and	O
plant	B-OG
kingdoms	O
[	O
17	O
].	O

Although	O
the	O
most	O
well	O
studied	O
role	O
for	O
piwi	B-GP
genes	O
is	O
in	O
the	O
germline	O
,	O
mammalian	O
piwi	B-GP
homologs	O
are	O
also	O
expressed	O
in	O
a	O
range	O
of	O
somatic	O
tissues	O
[	O
18	O
],	O
[	O
19	O
].	O

Understanding	O
molecular	O
mechanisms	O
underlying	O
hematopoiesis	O
has	O
important	O
clinical	O
implications	O
.	O

The	O
overexpression	O
of	O
mammalian	O
PIWI	B-GP
is	O
highly	O
correlated	O
to	O
pre	O
-	O
cancerous	O
hematopoietic	O
stem	O
cells	O
[	O
6	O
],	O
gastric	B-DS
cancers	I-DS
[	O
20	O
],	O
and	O
seminomas	B-DS
,	O
a	O
germline	O
-	O
derived	O
testicular	B-DS
cancers	I-DS
[	O
21	O
].	O

Additionally	O
,	O
human	B-OG
piwi	B-GP
transcripts	O
are	O
expressed	O
in	O
a	O
range	O
of	O
cancer	B-DS
cell	O
lines	O
and	O
in	O
cancer	B-DS
tissue	O
samples	O
[	O
5	O
],	O
[	O
20	O
]–[	O
29	O
].	O

Furthermore	O
,	O
a	O
recent	O
study	O
gave	O
evidence	O
that	O
the	O
P16INK4a	B-GP
tumor	B-GP
suppressor	I-GP
,	O
a	O
functional	O
unit	O
of	O
the	O
INK4	B-GP
/	O
ARF	B-GP
locus	O
,	O
is	O
directly	O
regulated	O
by	O
the	O
human	B-OG
PIWIL4	B-GP
gene	O
.	O

The	O
promoter	O
of	O
P16INK4a	B-GP
locus	O
contains	O
multiple	O
piRNA	O
sites	O
that	O
,	O
when	O
deleted	O
,	O
cause	O
mis	O
-	O
regulation	O
of	O
P16INK4	B-GP
protein	O
[	O
19	O
].	O

The	O
INK4	B-GP
/	O
ARF	B-GP
genomic	O
region	O
is	O
needed	O
during	O
normal	O
blood	O
development	O
to	O
facilitate	O
the	O
cell	O
death	O
response	O
of	O
bone	O
marrow	O
progenitor	O
cells	O
following	O
oncogenic	O
insult	O
and	O
is	O
commonly	O
deleted	O
in	O
leukemia	B-DS
[	O
30	O
].	O

Together	O
,	O
these	O
findings	O
open	O
the	O
possibility	O
that	O
PIWI	B-GP
proteins	O
might	O
play	O
important	O
roles	O
in	O
multiple	O
stem	O
cell	O
driven	O
tissues	O
,	O
including	O
the	O
blood	O
system	O
.	O

However	O
,	O
overexpression	O
studies	O
,	O
either	O
in	O
normal	O
or	O
cancerous	O
tissues	O
,	O
cannot	O
define	O
a	O
role	O
of	O
a	O
gene	O
during	O
normal	O
development	O
.	O

Therefore	O
,	O
the	O
requirement	O
of	O
PIWI	B-GP
proteins	O
in	O
hematopoiesis	O
,	O
remains	O
to	O
be	O
established	O
by	O
loss	O
-	O
of	O
-	O
function	O
studies	O
.	O

To	O
investigate	O
a	O
possible	O
function	O
of	O
piwi	B-GP
genes	O
in	O
hematopoiesis	O
,	O
we	O
created	O
a	O
triple	O
knockout	O
mouse	B-OG
model	O
in	O
which	O
all	O
three	O
piwi	B-GP
genes	O
,	O
Miwi	B-GP
(	O
Piwil1	B-GP
),	O
Mili	B-GP
(	O
Piwil2	B-GP
),	O
and	O
Miwi2	B-GP
(	O
Piwil4	B-GP
),	O
are	O
deleted	O
in	O
the	O
genome	O
.	O

Our	O
analysis	O
of	O
the	O
triple	O
knockout	O
mutants	O
illustrates	O
that	O
piwi	B-GP
genes	O
are	O
not	O
required	O
for	O
normal	O
adult	O
hematopoiesis	O
.	O

Materials	O
and	O
Methods	O

Ethics	O
Statement	O

Animal	B-OG
experiments	O
in	O
this	O
study	O
were	O
carried	O
out	O
in	O
accordance	O
with	O
the	O
Animal	B-OG
Use	O
Protocols	O
as	O
approved	O
by	O
the	O
Institutional	O
Animal	B-OG
Care	O
and	O
Use	O
Committee	O
,	O
Yale	O
University	O
(	O
IACUC	O
Protocol	O
number	O
:	O
2009	O
–	O
11087	O
).	O

Mouse	B-OG
blood	O
collection	O
was	O
performed	O
under	O
approved	O
anesthesia	O
,	O
and	O
all	O
efforts	O
were	O
made	O
to	O
minimize	O
suffering	O
.	O

Piwi	B-GP
knockout	O
mice	B-OG
strains	O

Mice	B-OG
carrying	O
deletions	O
for	O
single	O
piwi	B-GP
genes	O
were	O
generated	O
as	O
previously	O
described	O
in	O
refs	O
.	O
[	O
31	O
]–[	O
33	O
].	O

Triple	O
knockout	O
mice	B-OG
on	O
a	O
mixed	O
B6129S	O
genetic	O
background	O
were	O
generated	O
by	O
crossing	O
triple	O
heterozygous	O
males	O
with	O
triple	O
knockout	O
females	O
.	O

Genotypes	O
were	O
verified	O
using	O
multiplex	O
PCR	O
for	O
each	O
gene	O
with	O
the	O
following	O
primers	O
,	O
Miwi	B-GP
/	O
Piwil1	B-GP
:	O
5	O
′-	O
TTGAAAAGCATTGAACACCATAAG	O
–	O
3	O
′	O
and	O
5	O
’-	O
AGGTTG	O
CTGGCTCTGCTCATGAAT	O
–	O
3	O
′	O
and	O
5	O
′–	O
GACAGAAAATGACTGGCCGAGCCC	O
–	O
3	O
′	O
(	O
wild	O
-	O
type	O
=	O
400	O
bp	O
;	O
knockout	O
=	O
250	O
bp	O
);	O
Mili	B-GP
/	O
Piwil2	B-GP
:	O
5	O
′–	O
CGGCAGAGTGCAGTGAAGTTGG	O
–	O
3	O
′	O
and	O
5	O
′–	O
AAAGGAATGATGCACTTGAGGG	O
–	O
3	O
′	O
and	O
5	O
′–	O
GCTCCAGACTGCCTTGGG	O
–	O
3	O
′	O
(	O
wild	O
-	O
type	O
=	O
239	O
bp	O
;	O
knockout	O
=	O
100	O
bp	O
);	O
Miwi2	B-GP
/	O
Piwil4	B-GP
:	O
5	O
′-	O
AGTACCTTCCAAGTGGTG	O
–	O
3	O
′	O
and	O
5	O
′-	O
GTCCACCATCACCAGAAG	O
–	O
3	O
′	O
and	O
5	O
′-	O
CCTACCCGGTAGAATTGACC	O
–	O
3	O
′	O
and	O
5	O
′-	O
CAGCAACAATCATGCTAGA	O
–	O
3	O
′	O
(	O
wild	O
-	O
type	O
=	O
540	O
and	O
147	O
bp	O
;	O
knockout	O
=	O
300	O
bp	O
).	O

Bone	O
marrow	O
transplantation	O
and	O
5FU	O
treatment	O

For	O
competitive	O
repopulation	O
studies	O
,	O
1	O
×	O
106	O
CD45	B-GP
.	I-GP
2	I-GP
donor	O
and	O
1	O
×	O
106	O
CD45	B-GP
.	I-GP
1	I-GP
competitor	O
total	O
nucleated	O
bone	O
marrow	O
cells	O
were	O
mixed	O
and	O
injected	O
into	O
the	O
tail	O
veins	O
of	O
lethally	O
irradiated	O
CD45	B-GP
.	I-GP
1	I-GP
B6	O
Ly5	O
.	O
2	O
/	O
Cr	O
recipient	O
mice	B-OG
treated	O
with	O
9Gy	O
dose	O
via	O
Cesium	O
Irradiator	O
.	O

Hematopoietic	O
recovery	O
and	O
lineage	O
reconstitution	O
were	O
followed	O
by	O
serial	O
analysis	O
of	O
peripheral	O
blood	O
beginning	O
at	O
5	O
weeks	O
post	O
-	O
transplantation	O
.	O

Peripheral	O
blood	O
was	O
collected	O
by	O
retro	O
-	O
orbital	O
or	O
tail	O
vein	O
bleeding	O
methods	O
.	O

Enucleated	O
red	O
blood	O
cells	O
were	O
lysed	O
with	O
BD	O
FACS	O
Lysing	O
Solution	O
(	O
BD	O
Biosciences	O
)	O
following	O
manufacturer	O
'	O
s	O
protocol	O
and	O
remaining	O
cells	O
were	O
stained	O
with	O
antibodies	B-GP
to	O
detect	O
donor	O
derived	O
cells	O
and	O
committed	O
lineages	O
:	O
CD45	B-GP
.	I-GP
2	I-GP
-	O
FITC	O
,	O
B	O
cells	O
(	O
B220	B-GP
-	O
APC	B-GP
),	O
T	O
cells	O
(	O
CD3	B-GP
-	O
PE	B-GP
Cy5	O
),	O
Myeloid	O
(	O
CD11b	B-GP
-	O
PE	B-GP
).	O

Flow	O
cytometry	O
was	O
done	O
on	O
either	O
a	O
LSRII	O
(	O
BD	O
)	O
or	O
a	O
FACSCalibur	O
(	O
BD	O
).	O

Five	O
week	O
-	O
old	O
B6	O
Ly5	O
.	O
2	O
/	O
Cr	O
(	O
strain	O
01B96	O
)	O
recipient	O
mice	B-OG
were	O
purchased	O
from	O
the	O
National	O
Cancer	B-DS
Institute	O
Mouse	B-OG
Repository	O
(	O
Frederick	O
)	O
and	O
used	O
within	O
two	O
-	O
weeks	O
for	O
transplantation	O
experiments	O
.	O

All	O
animal	B-OG
studies	O
were	O
carried	O
out	O
as	O
approved	O
by	O
the	O
Yale	O
University	O
Institutional	O
Animal	B-OG
Care	O
and	O
Use	O
Committee	O
.	O

For	O
5FU	O
treatment	O
,	O
recipient	O
mice	B-OG
were	O
injected	O
at	O
20	O
weeks	O
post	O
-	O
competitive	O
transplant	O
(	O
as	O
described	O
above	O
)	O
via	O
intraperitoneal	O
route	O
with	O
25	O
mg	O
/	O
ml	O
5FU	O
at	O
a	O
dose	O
of	O
150	O
mg	O
/	O
kg	O
.	O

Recovery	O
from	O
HSC	O
stress	O
was	O
monitored	O
by	O
serial	O
sampling	O
of	O
peripheral	O
blood	O
subjected	O
to	O
Complete	O
Blood	O
Counts	O
(	O
CBC	O
)	O
and	O
FACS	O
analysis	O
of	O
committed	O
lineages	O
,	O
as	O
described	O
above	O
.	O

Quantitative	O
PCR	O

For	O
Real	O
-	O
time	O
quantitative	O
PCR	O
,	O
total	O
mRNA	O
was	O
extracted	O
from	O
FACS	O
sorted	O
bone	O
marrow	O
cells	O
using	O
either	O
RNeasy	O
Plus	O
Mini	O
kit	O
(	O
Qiagen	O
)	O
or	O
RNAqueous	O
-	O
Micro	O
Kit	O
(	O
Ambion	O
).	O

Mouse	B-OG
testis	O
RNA	O
was	O
extraction	O
with	O
Trizol	O
Reagent	O
(	O
Invitrogen	O
Life	O
Technologies	O
)	O
following	O
manufacturer	O
'	O
s	O
protocol	O
.	O

cDNA	O
was	O
prepared	O
using	O
High	O
-	O
Capacity	O
cDNA	O
Reverse	O
Transcription	O
Kit	O
(	O
Applied	O
Biosystems	O
)	O
and	O
real	O
-	O
time	O
quantitative	O
PCR	O
reactions	O
were	O
performed	O
on	O
a	O
Biorad	O
cycler	O
using	O
SybrGreen	O
detection	O
using	O
the	O
following	O
primers	O
for	O
Gapdh	B-GP
:	O
5	O
′-	O
CCAGGAGCGAGACCCCACTAACA	O
-	O
3	O
′	O
and	O
5	O
′-	O
TTCACACCCATCACAAACAT	O
-	O
3	O
′	O
(	O
177	O
bp	O
);	O
Miwi2	B-GP
/	O
Piwil4	B-GP
:	O
5	O
′-	O
CTGACCCGGACCTTGAATAA	O
-	O
3	O
′	O
and	O
5	O
′-	O
CGACCACCACATTCTTGTTG	O
-	O
3	O
′	O
(	O
175	O
bp	O
).	O

Cell	O
sorting	O
and	O
flow	O
cytometry	O

Bone	O
marrow	O
cells	O
were	O
obtained	O
from	O
hind	O
limbs	O
of	O
mice	B-OG
and	O
subjected	O
to	O
red	O
blood	O
cell	O
lysis	O
with	O
BD	O
Pharm	O
Lyse	O
(	O
BD	O
Biosciences	O
),	O
following	O
manufacturer	O
’	O
s	O
protocol	O
.	O

For	O
cell	O
sorting	O
,	O
lineage	O
depletion	O
for	O
isolation	O
of	O
HSC	O
and	O
progenitor	O
cell	O
populations	O
was	O
performed	O
by	O
immuno	O
-	O
magnetic	O
selection	O
using	O
Mouse	B-OG
Hematopoietic	O
Progenitor	O
(	O
Stem	O
)	O
Cell	O
Enrichment	O
Set	O
-	O
DM	O
(	O
BD	O
Biosciences	O
)	O
and	O
a	O
BD	O
IMag	O
Cell	O
Separation	O
Magnet	O
.	O

Following	O
depletion	O
,	O
cells	O
were	O
stained	O
simultaneously	O
with	O
Lineage	O
Cell	O
Detection	O
Cocktail	O
-	O
Biotin	O
(	O
Miltenyi	O
Biotec	O
)	O
and	O
an	O
antibody	B-GP
mix	O
containing	O
Sca	B-GP
-	O
PE	B-GP
,	O
cKit	B-GP
-	O
APC	B-GP
,	O
CD34	B-GP
-	O
FITC	O
,	O
IL7Ra	B-GP
-	O
PacBlue	O
,	O
CD16	B-GP
/	O
32	O
-	O
PeCy7	O
(	O
Progenitors	O
)	O
or	O
Sca	B-GP
-	O
PE	B-GP
,	O
cKit	B-GP
-	O
APC	B-GP
,	O
CD34	B-GP
-	O
FITC	O
,	O
CD48	B-GP
-	O
PacBlue	O
,	O
CD150	B-GP
-	O
PeCy7	O
(	O
HSC	O
),	O
followed	O
by	O
a	O
streptavidin	B-GP
-	O
PerCP	O
secondary	O
antibody	B-GP
alone	O
.	O

Immunophenotypes	O
were	O
defined	O
as	O
described	O
in	O
reference	O
[	O
34	O
]:	O
HSC	O
(	O
Lin	O
−	O
cKit	B-GP
+	O
Sca	B-GP
+	O
CD48	B-GP
−	O
CD150	B-GP
+),	O
MEP	O
(	O
Lin	O
−	O
cKit	B-GP
+	O
Sca	B-GP
−	O
CD34	B-GP
−	O
CD16	B-GP
/	O
32	O
−),	O
CMP	O
(	O
Lin	O
−	O
cKit	B-GP
+	O
Sca	B-GP
−	O
CD34	B-GP
+	O
CD16	B-GP
/	O
32	O
−),	O
and	O
GMP	O
(	O
Lin	O
−	O
cKit	B-GP
+	O
Sca	B-GP
−	O
CD34	B-GP
+	O
CD16	B-GP
/	O
32	O
+).	O

Bone	O
marrow	O
cells	O
used	O
for	O
Miwi2	B-GP
(	O
Piwil4	B-GP
)	O
real	O
-	O
time	O
PCR	O
were	O
stained	O
in	O
a	O
single	O
tube	O
,	O
following	O
lineage	O
depletion	O
,	O
with	O
an	O
antibody	B-GP
cocktail	O
including	O
Lineage	O
Cell	O
Detection	O
Cocktail	O
-	O
Biotin	O
(	O
Miltenyi	O
Biotec	O
),	O
Sca	B-GP
-	O
Alexa	O
-	O
647	O
,	O
cKit	B-GP
-	O
APCH7	O
,	O
CD150	B-GP
-	O
PECY5	O
,	O
CD105	B-GP
-	O
PECY7	O
,	O
and	O
CD16	B-GP
/	O
32	O
-	O
FITC	O
.	O

Immunophenotype	O
for	O
these	O
cells	O
was	O
defined	O
as	O
described	O
in	O
reference	O
[	O
35	O
]:	O
HSC	O
(	O
Lin	O
−	O
cKit	B-GP
+	O
Sca	B-GP
+	O
CD150	B-GP
+	O
CD105	B-GP
+),	O
multi	O
-	O
potent	O
progenitors	O
(	O
MPP	O
;	O
Lin	O
−	O
cKit	B-GP
+	O
Sca	B-GP
+	O
CD150	B-GP
−	O
CD105	B-GP
−),	O
and	O
GMP	O
(	O
Lin	O
−	O
cKit	B-GP
+	O
Sca	B-GP
−	O
CD150	B-GP
−	O
CD16	B-GP
/	O
32	O
+).	O

Lineage	O
positive	O
cell	O
types	O
were	O
purified	O
without	O
lineage	O
depletion	O
using	O
the	O
following	O
antibodies	B-GP
:	O
B	O
cells	O
(	O
B220	B-GP
-	O
PE	B-GP
),	O
T	O
cells	O
(	O
CD3	B-GP
-	O
PE	B-GP
),	O
Macrophages	O
(	O
Gr1	B-GP
-	O
PE	B-GP
,	O
CD11b	B-GP
-	O
FITC	O
),	O
Granulocytes	O
(	O
7	O
/	O
4	O
-	O
PE	B-GP
,	O
Gr1	B-GP
-	O
FITC	O
).	O

For	O
Flow	O
cytometry	O
analysis	O
,	O
lineage	O
depletion	O
was	O
not	O
used	O
for	O
HSC	O
and	O
progenitor	O
cell	O
analysis	O
.	O

Cell	O
sorting	O
was	O
done	O
on	O
a	O
FACS	O
Aria	O
Cell	O
Sorter	O
(	O
BD	O
)	O
and	O
Flow	O
cytometry	O
was	O
done	O
on	O
a	O
LSRII	O
(	O
BD	O
).	O

All	O
analysis	O
of	O
FACS	O
data	O
was	O
done	O
using	O
FloJo	O
Version	O
8	O
.	O
0	O
(	O
TreeStar	O
)	O
software	O
.	O

Colony	O
-	O
Forming	O
Unit	O
Assay	O

A	O
methylcellulose	O
-	O
based	O
assay	O
was	O
performed	O
whereby	O
bone	O
marrow	O
was	O
isolated	O
from	O
hind	O
limbs	O
of	O
control	O
or	O
Piwi	B-GP
triple	O
knockout	O
mice	B-OG
.	O

A	O
total	O
of	O
1	O
×	O
104	O
whole	O
bone	O
marrow	O
cells	O
were	O
mixed	O
with	O
Methocult	O
GF	O
M3434	O
(	O
StemCell	O
Technologies	O
)	O
containing	O
SCF	B-GP
,	O
IL	B-GP
-	I-GP
3	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
and	O
Erythropoietin	B-GP
.	O

Cells	O
from	O
each	O
mouse	B-OG
were	O
plated	O
in	O
triplicate	O
onto	O
35mm	O
dishes	O
and	O
incubated	O
at	O
37	O
°	O
C	O
,	O
5	O
%	O
CO2	O
with	O
high	O
humidity	O
.	O

Colonies	O
were	O
scored	O
after	O
seven	O
to	O
ten	O
days	O
by	O
counting	O
total	O
colony	O
numbers	O
for	O
each	O
replicate	O
plate	O
.	O

Complete	O
Blood	O
Counts	O
(	O
CBC	O
)	O

Total	O
peripheral	O
blood	O
was	O
collected	O
by	O
retro	O
-	O
orbital	O
or	O
tail	O
vein	O
bleeding	O
into	O
Capillary	O
Blood	O
Collection	O
Tubes	O
with	O
EDTA	O
(	O
BD	O
).	O

CBC	O
analysis	O
was	O
done	O
using	O
a	O
standard	O
mouse	B-OG
setting	O
on	O
a	O
Hemavet	O
950FS	O
(	O
DREW	O
Scientific	O
,	O
Inc	O
.).	O

Results	O

A	O
piwi	B-GP
gene	O
,	O
Miwi2	B-GP
,	O
is	O
expressed	O
in	O
the	O
adult	O
hematopoietic	O
cells	O

To	O
begin	O
our	O
investigation	O
,	O
we	O
examined	O
the	O
adult	O
hematopoietic	O
lineage	O
in	O
the	O
bone	O
marrow	O
for	O
expression	O
of	O
the	O
three	O
mouse	B-OG
piwi	B-GP
genes	O
.	O

Previous	O
studies	O
showed	O
that	O
the	O
expression	O
of	O
Miwi	B-GP
(	O
Piwil1	B-GP
)	O
and	O
Mili	B-GP
(	O
Piwil2	B-GP
)	O
is	O
not	O
detectable	O
significantly	O
above	O
the	O
background	O
in	O
hematopoietic	O
cells	O
,	O
[	O
6	O
],	O
[	O
29	O
].	O

Therefore	O
,	O
we	O
focused	O
on	O
the	O
Miwi2	B-GP
(	O
Piwil4	B-GP
)	O
gene	O
,	O
the	O
ortholog	O
of	O
HIWI2	B-GP
,	O
which	O
has	O
previously	O
shown	O
to	O
be	O
the	O
most	O
ubiquitously	O
expressed	O
human	B-OG
PIWI	B-GP
homolog	O
[	O
18	O
].	O

Using	O
RT	O
-	O
PCR	O
,	O
we	O
detected	O
high	O
levels	O
of	O
murine	O
Miwi2	B-GP
in	O
undifferentiated	O
cell	O
types	O
,	O
including	O
immunophenotypic	O
hematopoietic	O
stem	O
cells	O
(	O
HSC	O
;	O
Lin	O
-	O
cKit	B-GP
+	O
Sca	B-GP
+	O
CD150	B-GP
+	O
CD105	B-GP
+),	O
multi	O
-	O
potent	O
progenitors	O
(	O
MPP	O
;	O
Lin	O
−	O
cKit	B-GP
+	O
Sca	B-GP
+	O
CD150	B-GP
−	O
CD105	B-GP
−),	O
and	O
granulocyte	O
-	O
macrophage	O
progenitors	O
(	O
GMP	O
;	O
Lin	O
−	O
cKit	B-GP
+	O
Sca	B-GP
−	O
CD150	B-GP
−	O
CD16	B-GP
/	O
32	O
+),	O
as	O
compared	O
to	O
more	O
committed	O
cell	O
types	O
,	O
red	O
blood	O
cells	O
(	O
RBC	O
),	O
macrophages	O
(	O
Mac	O
),	O
neutrophils	O
(	O
Neutr	O
),	O
B	O
-	O
cells	O
,	O
and	O
T	O
-	O
cells	O
(	O
Fig	O
.	O
1	O
).	O

These	O
data	O
are	O
consistent	O
with	O
previously	O
published	O
results	O
for	O
human	B-OG
hematopoietic	O
cells	O
,	O
and	O
suggests	O
that	O
mouse	B-OG
piwi	B-GP
genes	O
may	O
have	O
a	O
regulatory	O
function	O
in	O
undifferentiated	O
cell	O
types	O
during	O
normal	O
hematopoiesis	O
.	O

The	O
mammalian	O
Miwi2	B-GP
gene	O
is	O
expressed	O
in	O
hematopoietic	O
stem	O
and	O
progenitor	O
cells	O
.	O

Real	O
-	O
time	O
PCR	O
of	O
FACS	O
sorted	O
young	O
adult	O
wild	O
-	O
type	O
mouse	B-OG
bone	O
marrow	O
cells	O
show	O
expression	O
of	O
Miwi2	B-GP
(	O
Piwil4	B-GP
)	O
at	O
elevated	O
levels	O
in	O
Lin	O
−	O
cell	O
types	O
,	O
hematopoietic	O
stem	O
cells	O
(	O
HSC	O
),	O
multi	O
-	O
potent	O
progenitors	O
(	O
MPP	O
)	O
and	O
granulocyte	O
-	O
macrophage	O
progenitors	O
(	O
GMP	O
),	O
but	O
at	O
low	O
or	O
undetectable	O
levels	O
in	O
Lin	O
+	O
cell	O
types	O
,	O
red	O
blood	O
cells	O
(	O
RBC	O
),	O
macrophages	O
(	O
Mac	O
),	O
neutrophils	O
(	O
Neutr	O
),	O
B	O
-	O
cells	O
,	O
and	O
T	O
-	O
cells	O
.	O

Quantitative	O
PCR	O
samples	O
were	O
normalized	O
to	O
Gapdh	B-GP
.	O

Data	O
is	O
the	O
average	O
of	O
triplicate	O
samples	O
from	O
combined	O
bone	O
marrow	O
from	O
three	O
mice	B-OG
.	O

As	O
indicated	O
,	O
the	O
difference	O
between	O
the	O
stem	O
/	O
progenitor	O
cell	O
types	O
and	O
the	O
differentiated	O
cell	O
types	O
is	O
statistically	O
significant	O
.	O
*	O
P	O
values	O
:	O
HSC	O
vs	O
:	O
MPP	O
=	O
0	O
.	O
667	O
,	O
GMP	O
=	O
0	O
.	O
078	O
,	O
RBC	O
=	O
0	O
.	O
012	O
,	O
Mac	O
=	O
0	O
.	O
006	O
,	O
Neutr	O
=	O
0	O
.	O
006	O
,	O
B	O
-	O
cell	O
=	O
0	O
.	O
012	O
,	O
T	O
-	O
cell	O
=	O
0	O
.	O
011	O
;	O
MPP	O
vs	O
:	O
GMP	O
=	O
0	O
.	O
146	O
,	O
RBC	O
=	O
0	O
.	O
043	O
,	O
Mac	O
=	O
0	O
.	O
028	O
,	O
Neutr	O
=	O
0	O
.	O
029	O
,	O
B	O
-	O
cell	O
=	O
0	O
.	O
044	O
,	O
T	O
-	O
cell	O
=	O
0	O
.	O
042	O
;	O
GMP	O
vs	O
:	O
RBC	O
=	O
0	O
.	O
015	O
,	O
Mac	O
=	O
0	O
.	O
012	O
,	O
Neutr	O
=	O
0	O
.	O
012	O
,	O
B	O
-	O
cell	O
=	O
0	O
.	O
015	O
,	O
T	O
-	O
cell	O
=	O
0	O
.	O
015	O
.	O
P	O
values	O
calculated	O
using	O
two	O
-	O
tailed	O
,	O
equal	O
variance	O
t	O
test	O
.	O

Piwi	B-GP
genes	O
are	O
dispensable	O
for	O
steady	O
-	O
state	O
hematopoiesis	O

Given	O
the	O
expression	O
of	O
Miwi2	B-GP
gene	O
products	O
in	O
the	O
hematopoietic	O
system	O
and	O
the	O
previously	O
published	O
influence	O
of	O
Mili	B-GP
overexpression	O
on	O
hematopoietic	O
cell	O
expansion	O
[	O
6	O
],	O
we	O
investigated	O
the	O
potential	O
function	O
of	O
piwi	B-GP
genes	O
in	O
maintaining	O
HSCs	O
and	O
hematopoietic	O
progenitors	O
during	O
hematopoiesis	O
in	O
mice	B-OG
.	O

To	O
avoid	O
the	O
complication	O
of	O
possible	O
functional	O
redundancy	O
,	O
we	O
utilized	O
a	O
triple	O
knockout	O
mouse	B-OG
model	O
whereby	O
the	O
three	O
piwi	B-GP
genes	O
are	O
simultaneously	O
deleted	O
,	O
leading	O
to	O
complete	O
loss	O
of	O
piwi	B-GP
expression	O
during	O
development	O
.	O

In	O
these	O
triple	O
-	O
knockout	O
mice	B-OG
,	O
total	O
peripheral	O
blood	O
leukocytes	O
,	O
erythrocytes	O
,	O
and	O
platelets	O
(	O
not	O
shown	O
)	O
are	O
similar	O
to	O
those	O
in	O
wild	O
-	O
type	O
and	O
triple	O
heterozygous	O
littermates	O
(	O
Fig	O
.	O
2A	O
),	O
suggesting	O
that	O
PIWI	B-GP
proteins	O
are	O
not	O
needed	O
for	O
mature	O
blood	O
cell	O
formation	O
.	O

Similarly	O
,	O
committed	O
cell	O
types	O
isolated	O
from	O
the	O
bone	O
marrow	O
of	O
young	O
adult	O
mice	B-OG
showed	O
no	O
difference	O
between	O
piwi	B-GP
mutant	O
and	O
wildtype	O
and	O
heterozygous	O
control	O
animals	B-OG
(	O
Fig	O
.	O
2B	O
).	O

Additionally	O
,	O
myeloid	O
colony	O
forming	O
unit	O
(	O
CFU	O
)	O
assays	O
were	O
performed	O
to	O
test	O
for	O
the	O
presence	O
of	O
myeloid	O
/	O
erythroid	O
progenitors	O
in	O
the	O
bone	O
marrow	O
.	O

Consistent	O
with	O
our	O
FACS	O
data	O
above	O
,	O
we	O
observed	O
no	O
difference	O
in	O
total	O
colony	O
numbers	O
between	O
the	O
triple	O
piwi	B-GP
mutant	O
and	O
wild	O
-	O
type	O
control	O
bone	O
marrow	O
(	O
Fig	O
.	O
2C	O
).	O

Deletion	O
of	O
all	O
three	O
piwi	B-GP
genes	O
causes	O
increased	O
HSC	O
frequency	O
,	O
but	O
does	O
not	O
affect	O
progenitor	O
or	O
committed	O
cell	O
type	O
numbers	O
.	O

Piwi	B-GP
-	O
triple	O
-	O
knockout	O
mature	O
blood	O
cell	O
numbers	O
are	O
unchanged	O
compared	O
to	O
control	O
mice	B-OG
(	O
WT	O
,	O
HET	O
),	O
as	O
determined	O
by	O
(	O
A	O
)	O
Complete	O
Blood	O
Cell	O
Count	O
(	O
CBC	O
)	O
for	O
white	O
blood	O
cells	O
(	O
WBC	O
),	O
neutrophils	O
(	O
NE	O
),	O
lymphocytes	O
(	O
LY	O
),	O
red	O
blood	O
cells	O
(	O
RBC	O
)	O
and	O
(	O
B	O
)	O
FACS	O
analysis	O
of	O
committed	O
bone	O
marrow	O
cell	O
types	O
(	O
A	O
:	O
WT	O
,	O
n	O
=	O
3	O
;	O
HET	O
,	O
n	O
=	O
4	O
;	O
triple	O
KO	O
,	O
n	O
=	O
4	O
;	O
B	O
:	O
WT	O
,	O
n	O
=	O
2	O
;	O
HET	O
,	O
n	O
=	O
3	O
,	O
triple	O
KO	O
,	O
n	O
=	O
3	O
).	O

(	O
C	O
)	O
Colony	O
Forming	O
Unit	O
(	O
CFU	O
)	O
assays	O
show	O
similar	O
total	O
myeloid	O
/	O
erythroid	O
progenitor	O
-	O
derived	O
colony	O
numbers	O
in	O
control	O
and	O
triple	O
Piwi	B-GP
mutant	O
bone	O
marrow	O
.	O

Colony	O
assays	O
used	O
total	O
bone	O
marrow	O
from	O
3	O
individual	O
mice	B-OG
for	O
each	O
genotype	O
.	O

Bone	O
marrow	O
samples	O
were	O
plated	O
in	O
triplicate	O
and	O
total	O
colonies	O
were	O
counted	O
at	O
days	O
7	O
–	O
10	O
.	O

Data	O
shown	O
as	O
the	O
average	O
total	O
colony	O
count	O
for	O
each	O
genotype	O
.	O

(	O
D	O
)	O
In	O
the	O
triple	O
Piwi	B-GP
mutant	O
,	O
the	O
percentage	O
of	O
bone	O
marrow	O
progenitors	O
(	O
CMP	O
,	O
MEP	O
and	O
GMP	O
)	O
are	O
only	O
moderately	O
increased	O
compared	O
to	O
control	O
mice	B-OG
progenitors	O
.	O

(	O
E	O
)	O
HSC	O
percentages	O
are	O
significantly	O
increased	O
in	O
Piwi	B-GP
triple	O
knockout	O
bone	O
marrow	O
.	O

(	O
F	O
)	O
Total	O
bone	O
marrow	O
cellularity	O
of	O
the	O
triple	O
knockout	O
mice	B-OG
is	O
almost	O
two	O
-	O
fold	O
reduced	O
compared	O
to	O
control	O
mice	B-OG
.	O

(	O
C	O
-	O
F	O
:	O
Control	O
,	O
n	O
=	O
4	O
;	O
triple	O
KO	O
,	O
n	O
=	O
4	O
).	O
P	O
values	O
calculated	O
using	O
two	O
-	O
tailed	O
,	O
unequal	O
variance	O
Student	O
'	O
s	O
t	O
test	O
.	O

To	O
examine	O
more	O
specifically	O
the	O
effect	O
of	O
Piwi	B-GP
deletion	O
in	O
the	O
hematopoietic	O
stem	O
and	O
progenitor	O
cell	O
compartment	O
,	O
we	O
analyzed	O
HSC	O
and	O
progenitor	O
percentages	O
in	O
mutant	O
versus	O
control	O
bone	O
marrow	O
by	O
FACS	O
analysis	O
.	O

While	O
progenitor	O
populations	O
for	O
common	O
myeloid	O
progenitors	O
(	O
CMP	O
),	O
myeloid	O
-	O
erythroid	O
progenitors	O
(	O
MEP	O
)	O
and	O
GMP	O
remained	O
unaffected	O
by	O
the	O
deletion	O
of	O
the	O
three	O
piwi	B-GP
genes	O
(	O
Fig	O
.	O
2D	O
),	O
we	O
did	O
note	O
an	O
almost	O
two	O
-	O
fold	O
increase	O
in	O
the	O
percentage	O
of	O
phenotypic	O
HSC	O
in	O
the	O
Piwi	B-GP
knockout	O
mice	B-OG
(	O
0	O
.	O
06	O
%)	O
as	O
compared	O
to	O
the	O
wildtype	O
and	O
heterozygous	O
control	O
mice	B-OG
bone	O
marrow	O
(	O
0	O
.	O
03	O
%,	O
Fig	O
.	O
2E	O
).	O

However	O
,	O
this	O
difference	O
was	O
offset	O
by	O
a	O
decrease	O
in	O
the	O
average	O
total	O
bone	O
marrow	O
cellularity	O
in	O
the	O
triple	O
mutant	O
as	O
compared	O
to	O
the	O
wild	O
-	O
type	O
control	O
mice	B-OG
(	O
1	O
.	O
7	O
×	O
107	O
HSC	O
and	O
2	O
.	O
8	O
×	O
107	O
HSC	O
,	O
respectively	O
,	O
Fig	O
.	O
2F	O
).	O

Therefore	O
,	O
the	O
total	O
number	O
of	O
triple	O
mutant	O
HSCs	O
in	O
bone	O
marrow	O
remains	O
similar	O
to	O
that	O
of	O
the	O
wild	O
-	O
type	O
with	O
an	O
average	O
of	O
1	O
×	O
104	O
HSCs	O
in	O
the	O
triple	O
mutant	O
as	O
compared	O
to	O
8	O
×	O
103	O
HSCs	O
in	O
control	O
marrow	O
.	O

Overall	O
,	O
our	O
data	O
indicate	O
that	O
there	O
is	O
no	O
significant	O
influence	O
of	O
triple	O
mutant	O
on	O
steady	O
-	O
state	O
hematopoiesis	O
.	O

Triple	O
piwi	B-GP
mutant	O
HSCs	O
can	O
sustain	O
hematopoiesis	O
as	O
assayed	O
by	O
competitive	O
transplantation	O

Because	O
hematopoietic	O
components	O
do	O
not	O
always	O
display	O
overt	O
phenotypes	O
when	O
disrupted	O
under	O
steady	O
-	O
state	O
conditions	O
and	O
subtle	O
differences	O
could	O
be	O
masked	O
by	O
the	O
strong	O
homeostatic	O
control	O
mechanisms	O
,	O
we	O
further	O
investigated	O
the	O
function	O
of	O
triple	O
mutant	O
HSCs	O
using	O
a	O
competitive	O
transplantation	O
assay	O
(	O
diagramed	O
in	O
Fig	O
.	O
3A	O
).	O

We	O
transplanted	O
equal	O
numbers	O
of	O
the	O
triple	O
mutant	O
or	O
control	O
whole	O
bone	O
marrow	O
,	O
expressing	O
the	O
CD45	B-GP
.	I-GP
2	I-GP
+	O
antigen	O
,	O
together	O
with	O
wild	O
-	O
type	O
CD45	B-GP
.	I-GP
1	I-GP
+	O
competitor	O
bone	O
marrow	O
,	O
into	O
lethally	O
irradiated	O
CD45	B-GP
.	I-GP
1	I-GP
+	O
mice	B-OG
.	O

This	O
antigen	O
marker	O
system	O
allows	O
for	O
tracking	O
of	O
hematopoiesis	O
of	O
donor	O
cells	O
within	O
the	O
transplanted	O
hosts	O
.	O

We	O
determined	O
the	O
proportion	O
of	O
donor	O
-	O
derived	O
CD45	B-GP
.	I-GP
2	I-GP
+	O
cells	O
in	O
the	O
recipient	O
mice	B-OG
by	O
analyzing	O
peripheral	O
blood	O
up	O
to	O
22	O
weeks	O
post	O
-	O
transplantation	O
.	O

The	O
triple	O
mutant	O
HSCs	O
constituted	O
a	O
slightly	O
elevated	O
proportion	O
of	O
the	O
blood	O
(	O
47	O
%)	O
compared	O
to	O
control	O
donor	O
-	O
derived	O
cells	O
(	O
39	O
%)	O
as	O
seen	O
by	O
ten	O
weeks	O
following	O
transplant	O
(	O
Fig	O
.	O
3B	O
).	O

However	O
,	O
a	O
continued	O
expansion	O
of	O
the	O
mutant	O
CD45	B-GP
.	I-GP
2	I-GP
-	O
derived	O
cells	O
did	O
not	O
occur	O
,	O
suggesting	O
that	O
PIWI	B-GP
deficiency	O
does	O
not	O
confer	O
any	O
long	O
-	O
term	O
repopulating	O
advantage	O
or	O
disadvantage	O
to	O
HSC	O
.	O

We	O
then	O
assessed	O
the	O
competitiveness	O
of	O
the	O
donor	O
-	O
derived	O
cells	O
in	O
giving	O
rise	O
to	O
various	O
lineages	O
,	O
by	O
looking	O
at	O
the	O
ratio	O
of	O
CD45	B-GP
.	I-GP
2	I-GP
+/	O
CD45	B-GP
.	I-GP
2	I-GP
−	O
cells	O
within	O
committed	O
cell	O
types	O
of	O
the	O
blood	O
system	O
including	O
T	O
-	O
cells	O
(	O
Fig	O
.	O
3C	O
),	O
B	O
-	O
cells	O
(	O
Fig	O
.	O
3D	O
),	O
and	O
myeloid	O
cells	O
(	O
Fig	O
.	O
3E	O
).	O

For	O
all	O
time	O
points	O
assessed	O
,	O
the	O
competitive	O
repopulation	O
ability	O
and	O
kinetics	O
of	O
the	O
triple	O
mutant	O
was	O
similar	O
to	O
the	O
wild	O
-	O
type	O
control	O
bone	O
marrow	O
-	O
derived	O
cell	O
types	O
.	O

To	O
confirm	O
establishment	O
of	O
mutant	O
and	O
control	O
cells	O
within	O
the	O
recipient	O
bone	O
marrow	O
,	O
CD45	B-GP
.	I-GP
2	I-GP
+	O
and	O
CD45	B-GP
.	I-GP
2	I-GP
−	O
bone	O
marrow	O
cells	O
were	O
isolated	O
by	O
FACS	O
from	O
representative	O
recipient	O
mice	B-OG
and	O
genotyped	O
for	O
individual	O
Piwi	B-GP
genes	O
.	O

All	O
mice	B-OG
showed	O
expected	O
genotypes	O
(	O
Fig	O
.	O

S1	O
).	O

Thus	O
,	O
triple	O
deletion	O
does	O
not	O
affect	O
the	O
ability	O
of	O
HSC	O
for	O
engraftment	O
or	O
in	O
supporting	O
normal	O
hematopoiesis	O
.	O

Piwi	B-GP
genes	O
are	O
not	O
required	O
for	O
marrow	O
HSC	O
engraftment	O
following	O
irradiation	O
.	O

(	O
A	O
)	O
Illustration	O
of	O
competitive	O
transplantation	O
scheme	O
whereby	O
the	O
triple	O
piwi	B-GP
mutant	O
or	O
control	O
donor	O
CD45	B-GP
.	I-GP
2	I-GP
+	O
bone	O
marrow	O
is	O
mixed	O
equally	O
with	O
competitor	O
CD45	B-GP
.	I-GP
1	I-GP
+	O
bone	O
marrow	O
and	O
injected	O
into	O
a	O
cohort	O
of	O
lethally	O
irradiated	O
CD45	B-GP
.	I-GP
1	I-GP
+	O
wild	O
-	O
type	O
recipient	O
mice	B-OG
.	O

(	O
B	O
)	O
Percentages	O
of	O
donor	O
-	O
derived	O
(	O
CD45	B-GP
.	I-GP
2	I-GP
+)	O
cells	O
from	O
the	O
triple	O
knockout	O
(	O
blue	O
circle	O
)	O
and	O
control	O
(	O
black	O
triangle	O
)	O
donors	O
in	O
the	O
peripheral	O
blood	O
of	O
lethally	O
irradiated	O
CD45	B-GP
.	I-GP
1	I-GP
+	O
recipient	O
mice	B-OG
,	O
measured	O
up	O
to	O
five	O
months	O
(	O
22	O
weeks	O
)	O
after	O
transplant	O
.	O

(	O
C	O
-	O
E	O
)	O
Ratio	O
of	O
donor	O
/	O
recipient	O
(	O
CD45	B-GP
.	I-GP
2	I-GP
+/	O
CD45	B-GP
.	I-GP
2	I-GP
−	O
)	O
derived	O
cells	O
within	O
committed	O
blood	O
cell	O
lineages	O
,	O
(	O
C	O
)	O
T	O
-	O
cell	O
(	O
CD3	B-GP
+),	O
(	O
D	O
)	O
B	O
-	O
cell	O
(	O
B220	B-GP
+),	O
and	O
(	O
E	O
)	O
myeloid	O
cells	O
(	O
CD11b	B-GP
+).	O

Data	O
is	O
the	O
average	O
of	O
two	O
independent	O
experiments	O
with	O
10	O
triple	O
Piwi	B-GP
mutant	O
injected	O
recipients	O
and	O
8	O
control	O
injected	O
recipients	O
from	O
each	O
experiment	O
.	O

Each	O
data	O
point	O
represents	O
the	O
mean	O
±	O
SEM	O
of	O
8	O
–	O
10	O
recipient	O
mice	B-OG
,	O
per	O
donor	O
genotype	O
.	O

The	O
triple	O
piwi	B-GP
mutant	O
recovers	O
normally	O
following	O
myeloablative	O
injury	O

One	O
of	O
the	O
key	O
functions	O
of	O
HSCs	O
is	O
to	O
replenish	O
the	O
lost	O
cells	O
following	O
tissue	O
injury	O
[	O
36	O
].	O

To	O
determine	O
a	O
role	O
for	O
piwi	B-GP
genes	O
in	O
HSC	O
injury	O
response	O
,	O
we	O
injected	O
mice	B-OG
with	O
the	O
widely	O
used	O
myeloablative	O
agent	O
5	O
-	O
fluorouracil	O
(	O
5FU	O
),	O
20	O
weeks	O
after	O
competitive	O
transplantation	O
(	O
as	O
described	O
above	O
),	O
when	O
homeostasis	O
had	O
long	O
been	O
re	O
-	O
established	O
.	O

We	O
then	O
used	O
FACS	O
analysis	O
of	O
peripheral	O
blood	O
cell	O
types	O
to	O
assess	O
the	O
recovery	O
process	O
by	O
the	O
established	O
Piwi	B-GP
mutant	O
or	O
control	O
HSCs	O
.	O

To	O
confirm	O
the	O
efficiency	O
of	O
the	O
5FU	O
treatment	O
,	O
Complete	O
Blood	O
Counts	O
(	O
CBC	O
)	O
analysis	O
showed	O
an	O
expected	O
drop	O
in	O
total	O
white	O
blood	O
cell	O
(	O
WBC	O
)	O
numbers	O
in	O
both	O
Piwi	B-GP
knockout	O
and	O
control	O
-	O
derived	O
cells	O
at	O
day	O
3	O
,	O
with	O
recovery	O
observed	O
by	O
around	O
day	O
14	O
(	O
Fig	O
.	O
4A	O
),	O
as	O
was	O
previously	O
reported	O
following	O
5FU	O
exposure	O
[	O
37	O
].	O

HSC	O
myeloablative	O
stress	O
response	O
is	O
not	O
affected	O
by	O
deletion	O
of	O
all	O
piwi	B-GP
genes	O
.	O

(	O
A	O
)	O
White	O
blood	O
cells	O
(	O
WBC	O
)	O
are	O
responsive	O
to	O
5FU	O
in	O
both	O
piwi	B-GP
triple	O
knockout	O
(	O
blue	O
circle	O
)	O
and	O
control	O
(	O
black	O
triangle	O
)	O
donor	O
-	O
derived	O
cells	O
.	O

(	O
B	O
)	O
Piwi	B-GP
triple	O
knockout	O
(	O
blue	O
circle	O
)	O
and	O
control	O
(	O
black	O
triangle	O
)	O
donor	O
-	O
derived	O
cells	O
(	O
CD45	B-GP
.	I-GP
2	I-GP
+)	O
show	O
similar	O
response	O
kinetics	O
following	O
5FU	O
,	O
measured	O
up	O
to	O
31	O
days	O
after	O
5FU	O
treatment	O
.	O

(	O
C	O
-	O
E	O
)	O
Ratio	O
of	O
donor	O
/	O
recipient	O
(	O
CD45	B-GP
.	I-GP
2	I-GP
+/	O
CD45	B-GP
.	I-GP
2	I-GP
−	O
)	O
derived	O
cells	O
from	O
Piwi	B-GP
triple	O
knockout	O
(	O
blue	O
circle	O
)	O
and	O
control	O
(	O
black	O
triangle	O
)	O
donors	O
in	O
mature	O
cell	O
populations	O
of	O
recipient	O
peripheral	O
blood	O
.	O

(	O
C	O
)	O
T	O
-	O
cell	O
(	O
CD3	B-GP
+),	O
(	O
D	O
)	O
B	O
-	O
cell	O
(	O
B220	B-GP
+),	O
and	O
(	O
E	O
)	O
myeloid	O
cell	O
(	O
CD11b	B-GP
+)	O
lineages	O
.	O

5FU	O
injection	O
point	O
is	O
indicated	O
as	O
a	O
black	O
arrow	O
on	O
each	O
graph	O
.	O

Data	O
is	O
the	O
average	O
of	O
10	O
triple	O
Piwi	B-GP
mutant	O
injected	O
recipients	O
and	O
9	O
control	O
injected	O
recipients	O
.	O

Each	O
data	O
point	O
represents	O
the	O
mean	O
±	O
SEM	O
of	O
8	O
–	O
10	O
recipient	O
mice	B-OG
,	O
per	O
donor	O
genotype	O
.	O

Analysis	O
of	O
peripheral	O
blood	O
donor	O
-	O
derived	O
CD45	B-GP
.	I-GP
2	I-GP
+	O
Piwi	B-GP
mutant	O
and	O
control	O
cells	O
showed	O
no	O
difference	O
in	O
injury	O
response	O
to	O
5	O
-	O
FU	O
treatment	O
.	O

A	O
transient	O
drop	O
in	O
donor	O
cell	O
percentages	O
was	O
observed	O
for	O
both	O
the	O
triple	O
mutant	O
and	O
control	O
-	O
derived	O
CD45	B-GP
.	I-GP
2	I-GP
+	O
cells	O
at	O
day	O
17	O
post	O
-	O
5FU	O
with	O
quick	O
recovery	O
noted	O
by	O
the	O
next	O
time	O
point	O
(	O
Fig	O
.	O
4B	O
).	O

This	O
drop	O
is	O
likely	O
due	O
to	O
a	O
technical	O
variation	O
at	O
this	O
time	O
-	O
point	O
.	O

Within	O
specific	O
lineages	O
,	O
the	O
recovery	O
of	O
B	O
-	O
cells	O
and	O
myeloid	O
cells	O
was	O
unaffected	O
by	O
PIWI	B-GP
deletion	O
(	O
Fig	O
.	O
4D	O
and	O
Fig	O
.	O
4E	O
,	O
respectively	O
).	O

A	O
slightly	O
less	O
dynamic	O
response	O
was	O
noted	O
for	O
Piwi	B-GP
mutant	O
-	O
derived	O
T	O
-	O
cells	O
(	O
Fig	O
.	O
4C	O
)	O
compared	O
to	O
control	O
-	O
derived	O
T	O
-	O
cells	O
.	O

However	O
,	O
there	O
is	O
a	O
high	O
amount	O
of	O
variability	O
between	O
individual	O
mice	B-OG
within	O
the	O
control	O
group	O
and	O
this	O
may	O
account	O
for	O
the	O
observed	O
fluctuations	O
in	O
T	O
-	O
cell	O
numbers	O
at	O
day	O
10	O
and	O
day	O
17	O
post	O
-	O
5FU	O
.	O

Overall	O
,	O
no	O
significant	O
difference	O
was	O
detected	O
between	O
the	O
triple	O
Piwi	B-GP
mutant	O
and	O
the	O
wild	O
-	O
type	O
control	O
with	O
respect	O
to	O
HSC	O
injury	O
response	O
.	O

Discussion	O

The	O
expression	O
of	O
piwi	B-GP
genes	O
in	O
undifferentiated	O
CD34	B-GP
+	O
cell	O
types	O
within	O
human	B-OG
bone	O
marrow	O
[	O
5	O
]	O
and	O
the	O
overexpression	O
study	O
of	O
PIWI	B-GP
proteins	O
in	O
human	B-OG
and	O
mouse	B-OG
leukemic	B-DS
cancer	I-DS
cells	O
raised	O
the	O
possibility	O
for	O
a	O
function	O
of	O
PIWI	B-GP
proteins	O
in	O
mammalian	O
hematopoiesis	O
.	O

Our	O
triple	O
piwi	B-GP
knockout	O
approach	O
has	O
allowed	O
us	O
to	O
definitively	O
address	O
this	O
question	O
.	O

We	O
identified	O
that	O
one	O
of	O
the	O
mouse	B-OG
piwi	B-GP
genes	O
,	O
Miwi2	B-GP
(	O
Piwil4	B-GP
),	O
is	O
specifically	O
expressed	O
in	O
immunophenotypically	O
isolated	O
HSCs	O
and	O
progenitors	O
of	O
adult	O
bone	O
marrow	O
,	O
but	O
not	O
in	O
committed	O
cell	O
types	O
.	O

However	O
,	O
despite	O
this	O
expression	O
,	O
our	O
findings	O
indicate	O
that	O
murine	O
PIWI	B-GP
proteins	O
do	O
not	O
significantly	O
contribute	O
to	O
the	O
ability	O
of	O
HSCs	O
to	O
maintain	O
hematopoiesis	O
or	O
the	O
proliferation	O
and	O
differentiation	O
of	O
their	O
progeny	O
under	O
homeostatic	O
conditions	O
in	O
adult	O
mice	B-OG
.	O

Furthermore	O
,	O
piwi	B-GP
genes	O
are	O
dispensable	O
for	O
HSC	O
recovery	O
from	O
competitive	O
and	O
replicative	O
stress	O
conditions	O
.	O

In	O
the	O
absence	O
of	O
all	O
three	O
piwi	B-GP
genes	O
,	O
the	O
number	O
of	O
phenotypic	O
HSCs	O
is	O
only	O
slightly	O
increased	O
compared	O
to	O
control	O
mice	B-OG
.	O

Additionally	O
,	O
the	O
triple	O
piwi	B-GP
mutant	O
hematopoietic	O
cells	O
were	O
able	O
to	O
maintain	O
normal	O
bone	O
marrow	O
progenitor	O
cell	O
populations	O
and	O
peripheral	O
blood	O
counts	O
.	O

This	O
indicates	O
that	O
piwi	B-GP
-	O
deficient	O
HSCs	O
are	O
able	O
to	O
maintain	O
a	O
balanced	O
hierarchy	O
of	O
downstream	O
lineage	O
committed	O
progeny	O
under	O
homeostatic	O
conditions	O
.	O

We	O
also	O
found	O
that	O
following	O
irradiation	O
and	O
in	O
the	O
presence	O
of	O
competitor	O
cells	O
,	O
the	O
triple	O
mutant	O
HSCs	O
were	O
functionally	O
competent	O
in	O
homing	O
to	O
the	O
bone	O
marrow	O
and	O
in	O
giving	O
rise	O
to	O
all	O
differentiated	O
lineage	O
cells	O
of	O
the	O
peripheral	O
blood	O
system	O
.	O

Additionally	O
,	O
the	O
triple	O
mutant	O
HSCs	O
are	O
able	O
to	O
appropriately	O
recover	O
from	O
5FU	O
-	O
induced	O
myeloablative	O
stress	O
with	O
similar	O
kinetics	O
to	O
the	O
control	O
mice	B-OG
.	O

While	O
the	O
observed	O
progression	O
of	O
hematopoiesis	O
in	O
the	O
triple	O
mutant	O
mice	B-OG
indicates	O
that	O
piwi	B-GP
genes	O
are	O
not	O
required	O
for	O
hematopoiesis	O
,	O
it	O
does	O
not	O
mean	O
that	O
these	O
proteins	O
are	O
involved	O
in	O
hematopoiesis	O
.	O

For	O
example	O
,	O
Piwi	B-GP
proteins	O
might	O
work	O
collectively	O
with	O
other	O
hematopoietic	O
regulators	O
in	O
a	O
functionally	O
redundant	O
fashion	O
,	O
so	O
that	O
additional	O
factors	O
would	O
need	O
to	O
be	O
mutated	O
simultaneously	O
with	O
the	O
piwi	B-GP
genes	O
in	O
order	O
to	O
see	O
a	O
tractable	O
effect	O
on	O
hematopoiesis	O
.	O

It	O
is	O
also	O
possible	O
that	O
in	O
order	O
to	O
detect	O
a	O
role	O
for	O
PIWI	B-GP
during	O
hematopoiesis	O
the	O
mice	B-OG
may	O
require	O
a	O
more	O
significant	O
physiological	O
or	O
environmental	O
challenge	O
that	O
is	O
not	O
available	O
within	O
our	O
assay	O
constraints	O
,	O
when	O
performed	O
under	O
stringent	O
laboratory	O
conditions	O
.	O

While	O
piwi	B-GP
genes	O
are	O
not	O
needed	O
to	O
maintain	O
normal	O
hematopoiesis	O
by	O
our	O
findings	O
,	O
their	O
aberrant	O
expression	O
has	O
been	O
correlated	O
with	O
cancerous	O
cell	O
states	O
in	O
many	O
different	O
tissue	O
types	O
.	O

Chen	O
and	O
colleagues	O
demonstrate	O
,	O
directed	O
overexpression	O
of	O
Mili	B-GP
(	O
Piwil2	B-GP
)	O
can	O
drive	O
proliferation	O
of	O
normal	O
bone	O
marrow	O
cells	O
in	O
culture	O
[	O
6	O
].	O

Another	O
recent	O
study	O
reported	O
that	O
the	O
progressive	O
differentiation	O
of	O
HSCs	O
to	O
restricted	O
lineages	O
is	O
characterized	O
by	O
tractable	O
chromatin	O
remodeling	O
at	O
lineage	O
specific	O
gene	O
loci	O
[	O
38	O
].	O

Because	O
cancer	B-DS
cells	O
are	O
characterized	O
by	O
hyper	O
-	O
proliferation	O
and	O
given	O
the	O
known	O
role	O
of	O
Piwi	B-GP
proteins	O
and	O
their	O
partner	O
piRNAs	O
in	O
epigenetic	O
regulation	O
[	O
31	O
],	O
[	O
39	O
]–[	O
41	O
],	O
it	O
would	O
be	O
interesting	O
to	O
further	O
examine	O
a	O
functional	O
role	O
for	O
piwi	B-GP
genes	O
during	O
malignant	O
hematpoietic	O
transformation	O
and	O
leukemic	O
progression	O
,	O
with	O
the	O
possibility	O
that	O
aberrant	O
PIWI	B-GP
expression	O
in	O
the	O
blood	O
system	O
can	O
drive	O
progenitors	O
to	O
uncontrolled	O
expansion	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
an	O
epigenetic	O
mechanism	O
.	O

Supporting	O
Information	O

Genotyping	O
of	O
transplanted	O
bone	O
marrow	O
cells	O
in	O
recipient	O
mice	B-OG
.	O
FACS	O
sorted	O
CD45	B-GP
.	I-GP
2	I-GP
+	O
and	O
CD45	B-GP
.	I-GP
2	I-GP
−	O
bone	O
marrow	O
cells	O
isolated	O
from	O
the	O
hind	O
limbs	O
of	O
representative	O
transplant	O
recipient	O
mice	B-OG
,	O
representing	O
Piwi	B-GP
triple	O
knockout	O
and	O
control	O
donor	O
cohorts	O
,	O
show	O
expected	O
genotypes	O
for	O
Miwi	B-GP
,	O
Mili	B-GP
,	O
and	O
Miwi2	B-GP
alleles	O
,	O
with	O
wild	O
-	O
type	O
and	O
heterozygous	O
expression	O
in	O
CD45	B-GP
.	I-GP
2	I-GP
+	O
cells	O
from	O
control	O
donor	O
mice	B-OG
(	O
601	O
and	O
603	O
)	O
and	O
knockout	O
alleles	O
for	O
CD45	B-GP
.	I-GP
2	I-GP
+	O
cells	O
from	O
triple	O
mutant	O
donor	O
mice	B-OG
(	O
610	O
and	O
613	O
).	O

CD45	B-GP
.	I-GP
2	I-GP
−	O
competitor	O
cells	O
and	O
wild	O
-	O
type	O
mouse	B-OG
tail	O
DNA	O
show	O
expected	O
wild	O
-	O
type	O
alleles	O
for	O
all	O
three	O
genes	O
.	O

For	O
isolation	O
,	O
nucleated	O
bone	O
marrow	O
cells	O
were	O
incubated	O
with	O
CD45	B-GP
.	I-GP
2	I-GP
-	O
FITC	O
antibody	B-GP
and	O
sorted	O
on	O
a	O
LSRII	O
(	O
BD	O
).	O

Genomic	O
DNA	O
was	O
then	O
purified	O
from	O
CD45	B-GP
.	I-GP
2	I-GP
+	O
and	O
CD45	B-GP
.	I-GP
2	I-GP
−	O
cells	O
and	O
used	O
for	O
PCR	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

